2024年1月18日,以色列Weizmann科学研究所的研究人员在Cell期刊发表了题为:Bispecific dendritic-T cell engager potentiates anti-tumor immunity的研究文章。 1.背景 使用抗PD-1(aPD-1)单克隆抗体的免疫检查点抑制治疗是一种有前景的癌症免疫治疗方法。然而,它对肿瘤免疫的影响范围较窄,因为大多数患者对该治疗没有反...
在这一发现的基础上,研究团队开发了一种双特异性树突状细胞-T细胞接合剂(Bispecific DC-T Cell Engager,BiCE)双抗,促进PD-1+T细胞和cDC1之间物理相互作用,该双抗的两个抗体臂分别连接两种不同细胞,一个与T细胞(CD8)结合,靶向PD-1,另一个树突状细胞(cDC1)结合,靶向CLEC9A。 在创造了这种BiCE双抗后,研究团队...
These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation. Here, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cell engager") ...
求翻译:Bispecific T cell-engager是什么意思?待解决 悬赏分:1 - 离问题结束还有 Bispecific T cell-engager问题补充:匿名 2013-05-23 12:21:38 双特异性T细胞接合 匿名 2013-05-23 12:23:18 (Bispecific T细胞允诺 匿名 2013-05-23 12:24:58 Bispecific T隐含对参与 匿名 2013-05-23 12:26:...
bispecific T cell engagers single-domain antibody CD1d Vγ9Vδ2-T cell type 1 NKT cell multiple myeloma acute myeloid leukemia chronic lymphocytic leukemia preclinical non-human primate Introduction T cell-engaging therapies are promising approaches in an expanding number of malignancies.1 Bispecific T...
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cell
Cell death mediated... P Waring,A Müllbacher - 《Immunology & Cell Biology》 被引量: 305发表: 1999年 Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Certain bispecific antibodies exhibit an extraordinary potency and ...
T. et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 74, 5561–5571 (2014). CAS PubMed Google Scholar Feucht, J. et al. T cell responses against CD19+pediatric acute lymphoblastic leukemia mediated by bispecific T cell engager (BiTE)...
L. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Curr. Opin. Biotechnol. 78, 102799 (2022). Article CAS PubMed Google Scholar Einsele, H. et al. The BiTE (bispecific T-cell engager) platform: development and future potential of a ...
The search strategy was based on the terms bispecific antibody, T cell engager, immune cell engager, antibody constructs, targeted delivery and variations of these terms. The ClinicalTrials.gov database was searched for trials evaluating bsAbs until September 5 2018, based on the abovementioned ...